Manipulation of T<sub>H</sub>17 responses in pulmonary immunity and disease through vaccination

Sonnenberg, Gregory F.; Weiner, David B.

doi:10.4161/hv.5.8.8879

Cited by 6 publications

(5 citation statements)

References 126 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Th1 polarization was confirmed by the high production of IFN-γ and very low release of IL-4 in culture supernatants of splenocytes in all immunized groups. A third type of inducible T cell immunity involves IL-17 production, a cytokine initially found to play a central role in inflammation and autoimmunity and now recognized as an important cytokine involved in normal responses to pathogens, such as those of the respiratory tract (Lu et al, 2008; Sonnenberg and Weiner, 2009), and in protective immunity induced by vaccination (Bettelli et al, 2007; Moffitt et al, 2011). Here we report the production of IL-17A in mice immunized by the IN route, while a lower IL-17A response was observed in mice primed-boosted by the SC route.…”

Section: Discussionmentioning

confidence: 99%

Prime-Boost Strategies in Mucosal Immunization Affect Local IgA Production and the Type of Th Response

Fiorino¹,

Pettini²,

Pozzi³

et al. 2013

Front. Immunol.

View full text Add to dashboard Cite

Combinations of different delivery routes for priming and boosting represent vaccination strategies that can modulate magnitude, quality, and localization of the immune response. A murine model was used to study T cell clonal expansion following intranasal (IN) or subcutaneous (SC) priming, and secondary immune responses after boosting by either homologous or heterologous routes. T cell primary activation was studied by using the adoptive transfer model of ovalbumin-specific transgenic CD4+ T cells. Both IN and SC immunization efficiently elicited, in the respective draining lymph nodes, primary clonal expansion of antigen-specific CD4+ T cells that disseminated toward distal lymph nodes (mesenteric and iliac) and the spleen. After boosting, a significant serum IgG response was induced in all groups independent of the combination of immunization routes used, while significant levels of local IgA were detected only in mice boosted by the IN route. Mucosal priming drove a stronger Th1 polarization than the systemic route, as shown by serum IgG subclass analysis. IFN-gamma production was observed in splenocytes of all groups, while prime-boost vaccine combinations that included the mucosal route, yielded higher levels of IL-17. Memory lymphocytes were identified in both spleen and draining lymph nodes in all immunized mice, with the highest number of IL-2 producing cells detected in mice primed and boosted by the nasal route. This work shows the critical role of immunization routes in modulating quality and localization of immune responses in prime-boost vaccine strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

Prime-Boost Strategies in Mucosal Immunization Affect Local IgA Production and the Type of Th Response

Fiorino¹,

Pettini²,

Pozzi³

et al. 2013

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Using DNA-based vaccinations for manipulating IL-17 T-cell responses might be an alternative. This approach can range from nonviral transfection (naked DNA or naked DNA loaded into liposomes) to viral transduction (DNA incorporated into a specific vector that targets the mucosal surface of the lung) (86). Although this approach may have great potential, it is even further away from clinical reality in the treatment of lung chronic lung disorders.…”

Section: Blockade Of the Adaptive Immune Systemmentioning

confidence: 99%

Innate and Adaptive Interleukin-17–producing Lymphocytes in Chronic Inflammatory Lung Disorders

Vanaudenaerde

Verleden²,

Vos³

et al. 2011

Am J Respir Crit Care Med

View full text Add to dashboard Cite

During T-cell receptor activation in a particular cytokine environment, naive CD4+ T cells may differentiate into lineages defined by their pattern of cytokine production and transcription factors: T helper type 1 (Th1), Th2, Th17, and Th22 cells; follicular helper T cells; and inducible regulatory T cells. Th17 cells have been recognized as a distinct lineage of Th cells, and associations between IL-17 and human disease have been known somewhat longer. It would be an oversimplification to restrict IL-17 to Th17 cells. Indeed, IL-17 is also expressed by other cells including IL-17-producing γδ T (γδ T-17) cells, natural killer T-17 cells, and IL-17-producing lymphoid tissue-induced cells. IL-17 was cloned in 1995 as a cytokine expressed by T cells, exerting inflammatory effects on epithelial, endothelial, and fibroblast cells. IL-17 is a solid link between innate and adaptive immunity and can exert both beneficial and deleterious effects. The discovery of IL-17 T cells has provided exciting new insights into host defense, immunoregulation, and autoimmunity. Unquestionably, data from mouse models have contributed enormously to our insight into immunological mechanisms. However, because of numerous differences between murine and human immunology, data obtained in mice are not simply interchangeable. We review IL-17 T cells exclusively in the human situation and more specifically their potential role in respiratory diseases. The advances in our understanding of IL-17 regulation offer opportunities to dissect the human IL-17 system and to reflect on the clinical presentation of lung diseases. More importantly, the IL-17 system allows us to speculate on new therapeutic opportunities. Some results have been previously reported in an abstract.

show abstract

“…Equally important in designing a safe vaccine is to measure IL‐17, which in various closely related forms, is elaborated by T helper type 17 (Th17) CD4 + T cells during innate and adaptive immune responses. The role of IL‐17 in vaccine design, however, has been controversial in that although it has been deemed important in protection against select microbial infections, it has also been deemed as a factor in generation and maintenance of auto‐immune responses . These data suggest that it is important to measure IL‐15 and IL‐17 in the innate and adaptive phases of the immune response in vaccine design.…”

Section: Introductionmentioning

confidence: 99%

Vitamin A or E and a catechin synergize as vaccine adjuvant to enhance immune responses in mice by induction of early interleukin‐15 but not interleukin‐1β responses

et al. 2016

View full text Add to dashboard Cite

Vitamins A and E and select flavonoids in the family of catechins are well-defined small molecules that, if proven to possess immunomodulatory properties, hold promise as vaccine adjuvants and various therapies. In an effort to determine the in vivo immunomodulatory properties of these molecules, we found that although mucosal and systemic vaccinations with a recombinant HIV-1 BaL gp120 with either a catechin, epigallo catechin gallate (EGCG) or pro-vitamin A (retinyl palmitate) alone in a vegetable-oil-in-water emulsion (OWE) suppressed antigen-specific responses, the combination of EGCG and vitamin A or E in OWE (Nutritive Immune-enhancing Delivery System, NIDS) synergistically enhanced adaptive B-cell, and CD4 + and CD8 + T-cell responses, following induction of relatively low local and systemic innate tumour necrosis factor-a (TNFa), interleukin-6 (IL-6) and IL-17, but relatively high levels of early systemic IL-15 responses. For induction of adaptive interferon-c and TNF-a responses by CD4 + and CD8 + T cells, the adjuvant effect of NIDS was dependent on both IL-15 and its receptor. In addition, the anti-oxidant activity of NIDS correlated positively with higher expression of the superoxide dismutase 1, an enzyme involved in reactive oxygen species elimination but negatively with secretion of IL-1b. This suggests that the mechanism of action of NIDS is dependent on anti-oxidant activity and IL-15, but independent of IL-1b and inflammasome formation. These data show that this approach in nutritive vaccine adjuvant design holds promise for the development of potentially safer effective vaccines.

show abstract

Manipulation of T_H17 responses in pulmonary immunity and disease through vaccination

Cited by 6 publications

References 126 publications

Prime-Boost Strategies in Mucosal Immunization Affect Local IgA Production and the Type of Th Response

Prime-Boost Strategies in Mucosal Immunization Affect Local IgA Production and the Type of Th Response

Innate and Adaptive Interleukin-17–producing Lymphocytes in Chronic Inflammatory Lung Disorders

Vitamin A or E and a catechin synergize as vaccine adjuvant to enhance immune responses in mice by induction of early interleukin‐15 but not interleukin‐1β responses

Contact Info

Product

Resources

About

Manipulation of TH17 responses in pulmonary immunity and disease through vaccination

Cited by 6 publications

References 126 publications

Prime-Boost Strategies in Mucosal Immunization Affect Local IgA Production and the Type of Th Response

Prime-Boost Strategies in Mucosal Immunization Affect Local IgA Production and the Type of Th Response

Innate and Adaptive Interleukin-17–producing Lymphocytes in Chronic Inflammatory Lung Disorders

Vitamin A or E and a catechin synergize as vaccine adjuvant to enhance immune responses in mice by induction of early interleukin‐15 but not interleukin‐1β responses

Contact Info

Product

Resources

About

Manipulation of T_H17 responses in pulmonary immunity and disease through vaccination